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PARENTERAL PARECOXIB FOLLOWED BY ORAL
VALDECOXIB AFTER MAJOR GENERAL SURGERY REDUCES
OPIOID CONSUMPTION AND OPIOID-RELATED SYMPTOMS
Katz JA1, Ferrante FM2, Neumann J3, Rowinski W4,Trzebicki J4,
Kosieradzki M4, Brown MT5, Boye M5
1Northwestern University Medical Center, Chicago, IL, USA; 2UCLA,
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OBJECTIVES: To evaluate the clinical beneﬁt of reduced opioid
consumption using multimodal analgesia with intravenous (IV)
and oral cyclooxygenase-2 (COX-2) speciﬁc inhibitors in 
combination with conventional analgesia vs conventional 
analgesia alone, in patients undergoing major general surgery.
METHODS: In this double-blind, placebo-controlled trial,
patients were randomized to parecoxib/valdecoxib (n = 533)
parecoxib 40mg IV on Day-one (day of surgery) then 20mg
IV/IM [intramuscular] q12h for three-days, then oral valdecoxib
20mg q12h) for seven-days or placebo (n = 529). Supplemental
analgesia was patient-controlled morphine during IV/IM dosing,
and codeine/acetaminophen or hydrocodone/acetaminophen
during oral dosing. Beginning Day-two, the patient-reported
Opioid-Related Symptom Distress Scale (OR-SDS)—an original,
validated instrument—was administered nightly at bedtime to
assess ten opioid-related adverse effects. Patient distress attrib-
uted to each opioid-related adverse effect was assessed using
verbal rating scales for frequency, severity, and bother, with clin-
ically meaningful adverse effects (CMEs) deﬁned as those rated
as having occurred at least “frequently” or with at least “severe”
intensity or resulting in at least a “somewhat bothered” level of
distress. RESULTS: Opioid consumption was reduced by 37%
(P < 0.001), 28% (P < 0.004), and 38% (P < 0.002) with pare-
coxib/valdecoxib vs. placebo on days two to four, respectively.
Randomization to parecoxib/valdecoxib resulted in signiﬁcantly
reduced risk of clinically meaningful drowsiness (nominal P <
0.001) and fatigue (nominal P < 0.001). Across the ten OR-SDS
adverse effects, 73% (378/520), 58% (291/502), and 46%
(226/496) of patients randomized to placebo reported at least
one CME on days two to four, respectively, compared with 
corresponding rates of 59% (307/520), 42% (215/512), and
28% (142/499) in the parecoxib/valdecoxib treatment group 
(P < 0.001). CONCLUSION: Compared with standard analge-
sia alone, treatment with parecoxib/valdecoxib plus standard
analgesia after major general surgery signiﬁcantly reduced opioid
consumption and patient days with opioid-related CMEs. Newly
developed OR-SDS is a useful validated instrument in docu-
menting these ﬁndings.
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OBJECTIVE: To assess the cardiovascular risk factors at 
baseline in Dutch patients prescribed cyclooxygenase-2
inhibitors (coxibs) compared to nonselective nonsteroidal anti-
inﬂammatory drugs (NSAIDs). METHODS: Data were obtained
from the PHARMO database, which includes linked drug-dis-
pensing records and hospital records of more than one million
subjects in deﬁned areas in the Netherlands. All users of cele-
coxib, rofecoxib or NSAIDs in the period January, 2001—
December, 2003 were included in this retrospective population
based cohort study. The presence of cardiovascular risk factors
based on hospital admissions and drug use was compared in the
year before the ﬁrst prescription between users of coxibs or
NSAIDs using logistic regression analyses. RESULTS: The cohort
consisted of approximately 4,000 users of celecoxib, 34,000
users of rofecoxib and 326,000 users of NSAIDs. Users of coxibs
more often were female (68% vs. 56%) and of higher age
(average of 56 years vs. 45 years) compared to users of NSAIDs.
Multivariate analyses including gender, age and prescriber
showed that patients using celecoxib 1.3 times (95%CI:
1.05–1.59) more often had a history of hospital admissions for
cardiovascular diseases compared to patients using NSAIDs.
This association was not signiﬁcant for users of rofecoxib. Other
factors positively associated with the use of coxibs were previ-
ous hospitalizations for RA, OA and other diagnoses and previ-
ous use of gastroprotective agents. CONCLUSIONS: In general,
users of coxibs seem to be less healthy then users of NSAIDs with
higher cardiovascular risk factors at baseline. This difference
should be taken into account when investigating the possible
association between cardiovascular adverse events and use of
coxibs.
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ECONOMIC EVALUATION OF CONTROLLED-RELEASE
OXYCODONE (OXYCONTIN® TABLETS) (CRO) VERSUS
OXYCODONE/ACETAMINOPHEN (PERCOCET®) (OXY/APAP)
FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE
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Kim S2,Torrance G1
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OBJECTIVES: CRO is efﬁcacious for persistent moderate to
severe osteoarthritis pain based on well-controlled trials. Addi-
tionally, decision-makers require evidence of effectiveness in
routine practice, and cost-effectiveness compared to standard
therapy. METHODS: Open-label, active-controlled, random-
ized, naturalistic four-month study of analgesic effectiveness and
cost-effectiveness of CRO vs. oxy/APAP. Outcomes and resource
use were collected by telephone. Effectiveness was measured in
485 patients as the proportion having at least 20% improvement
from baseline in Western Ontario and McMaster Universities
Osteoarthritis Index pain score. Quality-adjusted-life-years
(QALYs) were calculated from Health Utilities Index-3 scores.
Cost-effectiveness was measured as cost/patient improved and
QALYs gained from societal and health care perspectives using
generic oxy/APAP (base case). Uncertainty was evaluated using
multiple one-way sensitivity analyses and cost-effectiveness
acceptability curves. RESULTS: In total, 62.2% vs. 45.9% (p =
0.0003) of patients improved with CRO and oxy/APAP respec-
tively. Mean QALYs gained over four months with CRO com-
pared to oxy/APAP was 0.0105 (p = 0.1673). Mean societal
cost/patient over four months was US$6792 vs. US$6929 (p =
0.3345) for CRO and oxy/APAP, respectively. CRO was both
more effective and less costly than oxy/APAP using the societal
perspective (includes costs associated with time loss). Using a
health care perspective (excludes costs associated with time loss),
cost-effectiveness of CRO was US$4,500/patient improved and
US$69,856/QALY gained. CONCLUSIONS: From the societal
perspective, CRO was both more effective and less costly than
oxy/APAP. From the health care perspective, CRO compared to
generic oxy/APAP fell within the acceptable range of cost-
effectiveness if decision-makers were willing-to-pay between
US$50,000/QALY and US$100,000/QALY. These ﬁndings
should be considered in decisions about treating osteoarthritis
pain.
